Key result
High-dose elamipretide significantly decreased left ventricular end-diastolic volume (-18 mL; P=0.009) and end-systolic volume (-14 mL; P=0.005) compared with placebo.
Why the study?
Does a single infusion of elamipretide improve cardiac structure and function and is it safe in patients with heart failure with reduced ejection fraction?
Population
36 patients with heart failure with reduced ejection fraction (ejection fraction ≤35%)
Comparison
Single 4-hour infusion of elamipretide at… vs Placebo control (n=12)
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
24 hours postinfusion start
Authors
Loading...
Supports acute elamipretide evaluation in HFrEF; extends mitochondrial-targeted therapy evidence from this RCT.
RCT (n=36)
Double-blind
randomized
Does a single infusion of elamipretide improve cardiac structure and function and is it safe in patients with heart failure with reduced ejection fraction?
Mean Difference: -18
p-value: p=0.009 for LVEDV, 0.005 for LVESV
A single infusion of the novel mitochondria-targeting peptide elamipretide is safe and acutely reduces left ventricular volumes in patients with HFrEF.
Daubert et al. (2017) conducted an RCT in Heart failure with reduced ejection fraction (n=36). Elamipretide vs. Placebo was evaluated on Left ventricular end-diastolic volume and end-systolic volume (MD -18 mL for LVEDV, -14 mL for LVESV, p=0.009 for LVEDV, 0.005 for LVESV). High-dose elamipretide significantly decreased left ventricular end-diastolic volume (-18 mL; P=0.009) and end-systolic volume (-14 mL; P=0.005) compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: